Thus, PIKFYVE inhibitors, either alone or in combination with other targeted drugs (including ectopic IL24 protein) exhibit significant therapeutic potential against PIKFYVE‐sensitive cancers, particularly melanoma that express high levels of endogenous IL24. This evidence concerns the gene PIKFYVE and melanoma.